The number of votes in BioGaia decreased during May as a result of the conversion of a total of 1,038,202 Class A shares into 1,038,202 Class B shares. The conversion was carried out based on the provision in the Articles of Association, introduced at the Annual General Meeting on May 7, 2025, allowing Class A shareholders to request conversion of Class A shares into Class B shares.
As of May 30, 2025, the total number of shares in BioGaia amounts to 101,162,310 of which 2,665,138 are Class A shares with ten votes each and 98,497,172 are Class B shares with one vote each, totaling 125,148,552 votes. Additionally, the share capital amounts to SEK 20,232,462.
As of May 30, 2025, BioGaia holds no treasury shares.
Follow us:
Subscribe to BioGaia press releases here
LinkedIn here
Contacts:
Alexander Kotsinas, CFO
Email: alexander.kotsinas@biogaia.com
Phone: +46(0) 735 00 11 11
Mikaela Idermark Stern, Corporate Communications
Email: mikaela.idermark.stern@biogaia.com
Phone: +46(0) 730 95 61 50
About BioGaia
BioGaia is a Swedish probiotic company that has been at the forefront of microbiome research for more than 35 years. BioGaia develops, markets, and sells probiotic products focused on gut health, immune health, and oral health. The products are sold through local distribution partners or via own distribution in over 100 markets. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaiagroup.com
This disclosure contains information that BioGaia AB (publ) is obliged to make public pursuant to the Swedish Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person, on May 30, 2025, at 11:00 CEST.